title: Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.
abstract: Recent research provided important insights into the development of atrial fibrillation (AF)-maintaining substrate and suggested targeting of the underlying molecular mechanisms, 'upstream' of the electrical aspects of AF, as a novel strategy for AF treatment ('upstream' therapy). Upstream therapies for AF include drugs targeting the renin-angiotensin II-aldosterone system (angiotensin converting enzyme inhibitors and AT(1) receptor antagonists and aldosterone antagonists), statins, steroids and omega-3 fatty acids (fish oil). Aldosterone causes volume retention, cardiac hypertrophy and fibrosis, and systemic inflammation and coagulation that promote AF development and its complications and blockade of aldosterone receptors with spironolactone or eplerenone suppresses inducible AF. Although the clinical impact of spironolactone treatment requires validation in randomized clinical trials in AF patients, further understanding of the molecular mechanisms by which aldosterone causes atrial remodelling is likely to lead to development of novel therapeutic approaches to AF.
authors.affiliation: Institute of Medical Biochemistry and Molecular Biology, Ernst-Moritz-Arndt University Greifswald, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Lendeckel
authors.forename: Dobromir
authors.initials: D
authors.lastname: Dobrev
authors.forename: Andreas
authors.initials: A
authors.lastname: Goette
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy*; D000077545:Eplerenone; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone
references.citation: Eur Heart J. 2005 Oct;26(20):2193-9
references.pmid: 16141258
references.citation: Cardiovasc Res. 1997 Jul;35(1):138-47
references.pmid: 9302358
references.citation: Zhonghua Yi Xue Za Zhi. 2007 Mar 27;87(12):816-9
references.pmid: 17565863
references.citation: Br J Pharmacol. 2010 Apr;159(8):1584-94
references.pmid: 20082611
references.citation: J Am Coll Cardiol. 2000 May;35(6):1669-77
references.pmid: 10807475
references.citation: Cardiovasc Res. 2007 Dec 1;76(3):506-16
references.pmid: 17706954
references.citation: Circulation. 2000 Jun 13;101(23):2678-81
references.pmid: 10851203
references.citation: Circulation. 2009 Apr 28;119(16):2179-87
references.pmid: 19364981
references.citation: Am J Cardiol. 2001 Oct 15;88(8):906-9, A8
references.pmid: 11676961
references.citation: J Cardiovasc Electrophysiol. 2006 May;17(5):534-41
references.pmid: 16684029
references.citation: Circ Res. 2009 Oct 23;105(9):852-9
references.pmid: 19762686